Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

NCT05098132 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

364

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor
Non Small Cell Lung Cancer
Untreated Advanced NSCLC
1st Line NSCLC

Interventions

DRUG: STK-012
DRUG: pembrolizumab
DRUG: pemetrexed
DRUG: carboplatin

Sponsor

Synthekine